The adoption of biosimilar medicines depends on many factors, such as pricing and public procurement policies, patient and healthcare professional training, and the availability of incentives for prescribing them. For this reason, the use of these medicines, despite increasing year after year, shows considerable variability between countries.

With the aim of comparing how each health system has integrated these therapies into the therapeutic arsenal of each country, this section presents the adoption data of biosimilars of several active ingredients since 2020 (or since their year of arrival on the market in each of the countries).

The data is presented graphically, facilitating the visualization of trends and differences between countries to provide a complete view of the use of biosimilars in different European healthcare systems.

*Data source: Spanish Ministry of Health and various organizations in each country (see methodological note).